EGFR and non-small cell lung carcinoma: Having been demonstrated synergy therapeutic efficient when combined with targeted therapies in hematologic malignancies, the navitoclax exhibited compelling clinical efficacy when combined with Osimertinib for EGFR-mutant NSCLC patients in a phase IB clinical study (NCT02520778) [40].